You are here

Article Text

Article menu
Download PDFPDF
Poster exhibition Day 2
P135 Discovery and validation of novel biomarkers for detection of epithelial ovarian cancer
  1. H Kulbe1,
  2. R Otto2,
  3. S Darb-Esfahani3,
  4. H Lammert3,
  5. S Abobaker1,
  6. G Welsch3,
  7. R Chekerov1,
  8. R Schäfer3,
  9. D Dragun3,
  10. M Hummel3,
  11. U Leser2,
  12. J Sehouli1 and
  13. E Braicu1
  1. 1Department of Gynecology, European Competence Center for Ovarian Cancer, Campus Virchow Clinic, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Department of Gynecology, European Competence Center for Ovarian Cancer, Campus Virchow Clinic
  2. 2Institute for Computer Sciences, Humboldt-Universität zu Berlin
  3. 3Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany

Abstract

Introduction/Background Early detection of epithelial ovarian cancer (EOC) is poses a critical medical challenge, however, novel biomarkers for early diagnosis remain to be discovered. Here, we investigate both epithelial and stromal compartments, which have been neglected in the past in search for novel candidates.

Methodology We queried gene expression profiles of microdissected epithelium and adjacent stroma from benign and malignant tumors (GSE29156) and normal epithelium samples (GSE14407). Genes significantly differentially expressed within either the epithelial or specifically the stromal compartments were retrieved. The expression of genes whose products are secreted yet absent in the blood of healthy donors were validated in tissue and blood from patients with pelvic mass by NanoString analysis. Results were confirmed by the independent gene expression database CSIOVDB.

Results Top 25% of candidate genes were validated, twelve were able to discriminate between benign and malignant tumors on transcript levels (p<0.05). The stroma-derived candidates versican (VCAN) and syndecan-3 (SDC3) were increased in blood of patients with EOC ovarian cancer compared with benign gynecological conditions. Transcript levels of the nuclear orphan receptor NR2F6, denticleless E3 ubiquitin protein ligase DTL, myelin and lymphocyte protein MAL, aurora kinase A (AURKA), VCAN and SDC3 genes performed significantly better than those of known biomarkers to discern malignant from benign conditions. Furthermore, elevated MAL and AURKA expression levels correlated significantly with poor prognosis.

Conclusion We identified promising novel candidates and found the stroma of ovarian cancer to be a suitable compartment for early detection biomarker discovery.

Disclosure Nothing to disclose.

https://doi.org/10.1136/ijgc-2019-ESGO.197

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.